Log in to view full text
As a service to the community this article is available to view for free. Use your via AAAS ID to log in or register for a free account
Research Article
Targeting DnaN for tuberculosis therapy using novel griselimycins
- Angela Kling1,2,*,
- Peer Lukat1,2,3,*,
- Deepak V. Almeida4,5,
- Armin Bauer6,
- Evelyne Fontaine7,
- Sylvie Sordello7,
- Nestor Zaburannyi1,2,
- Jennifer Herrmann1,2,
- Silke C. Wenzel1,2,
- Claudia König6,
- Nicole C. Ammerman4,5,
- María Belén Barrio7,
- Kai Borchers6,
- Florence Bordon-Pallier8,
- Mark Brönstrup3,6,
- Gilles Courtemanche7,
- Martin Gerlitz6,
- Michel Geslin7,
- Peter Hammann9,
- Dirk W. Heinz2,3,
- Holger Hoffmann6,
- Sylvie Klieber10,
- Markus Kohlmann6,
- Michael Kurz6,
- Christine Lair7,
- Hans Matter6,
- Eric Nuermberger4,
- Sandeep Tyagi4,
- Laurent Fraisse7,
- Jacques H. Grosset4,5,
- Sophie Lagrange7,
- Rolf Müller1,2,†
- 1Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.
- 2German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
- 3Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
- 4Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
- 5KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban 4001, South Africa.
- 6Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
- 7Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
- 8Sanofi-Aventis R&D, Strategy, Science Policy & External Innovation (S&I), 75008 Paris, France.
- 9Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 65926 Frankfurt, Germany.
- 10Sanofi-Aventis R&D, Disposition Safety and Animal Research, 34184 Montpellier, France.
- ↵†Corresponding author. E-mail: rolf.mueller{at}helmholtz-hzi.de
↵* These authors contributed equally to this work.
+ See all authors and affiliations
Science 05 Jun 2015:
Vol. 348, Issue 6239, pp. 1106-1112
DOI: 10.1126/science.aaa4690
Vol. 348, Issue 6239, pp. 1106-1112
DOI: 10.1126/science.aaa4690
Angela Kling
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
Peer Lukat
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Deepak V. Almeida
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban 4001, South Africa.
Armin Bauer
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Evelyne Fontaine
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Sylvie Sordello
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Nestor Zaburannyi
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
Jennifer Herrmann
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
Silke C. Wenzel
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
Claudia König
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Nicole C. Ammerman
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban 4001, South Africa.
María Belén Barrio
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Kai Borchers
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Florence Bordon-Pallier
Sanofi-Aventis R&D, Strategy, Science Policy & External Innovation (S&I), 75008 Paris, France.
Mark Brönstrup
Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Gilles Courtemanche
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Martin Gerlitz
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Michel Geslin
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Peter Hammann
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 65926 Frankfurt, Germany.
Dirk W. Heinz
German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany.
Holger Hoffmann
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Sylvie Klieber
Sanofi-Aventis R&D, Disposition Safety and Animal Research, 34184 Montpellier, France.
Markus Kohlmann
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Michael Kurz
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Christine Lair
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Hans Matter
Sanofi-Aventis R&D, LGCR/Chemistry, Industriepark Höchst, 65926 Frankfurt am Main, Germany.
Eric Nuermberger
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Sandeep Tyagi
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Laurent Fraisse
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Jacques H. Grosset
Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban 4001, South Africa.
Sophie Lagrange
Sanofi-Aventis R&D, Infectious Diseases Therapeutic Strategic Unit, 31036 Toulouse, France.
Rolf Müller
Department of Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research and Pharmaceutical Biotechnology, Saarland University, 66123 Saarbrücken, Germany.German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany.
